The French journal of urology · 2026
Diagnostic performance of 29-MHz micro-ultrasound using cognitive fusion with multiparametric MRI for the detection of clinically significant prostate cancer: a single-center retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Idri Cedric, Michel Floriane, Soulie Michel, Thoulouzan Matthieu, Doumerc Nicolas, Roumiguie Mathieu, Brierre Thibaut, Game Xavier, Bajeot Anne-Sophie
Аннотация
INTRODUCTION: The aim of this study was to evaluate the diagnostic performance of 29-MHZ micro-ultrasound with cognitive fusion based on multiparametric MRI for the detection of clinically significant prostate cancer.
MATERIALS AND METHODS: A single-center retrospective study included 185 patients who underwent targeted prostate biopsies between January 2022 and December 2023. Biopsies were all performed with a 29-MHz high-resolution micro-ultrasound system, combined with cognitive fusion based on prior prostate MRI. Primary endpoint was the detection rate of clinically significant prostate cancer defined as ISUP grade ≥ 2. MRI-ultrasound discordances were also analysed, as well as the diagnostic performance of the PRI-MUS score.
RESULTS: The overall prostate cancer detection rate was 68%, with a clinically significant cancer detection rate of 47%. MRI-ultrasound concordance was observed in 152 patients, with a 50% detection rate for ISUP grade ≥ 2 cancers. Among ultrasound targets not identified on MRI, three clinically significant cancers were detected. The PRI-MUS score showed a sensitivity of 75%, a specificity of 36%, and an AUC of 0.66.
CONCLUSION: 29-MHz micro-ultrasound combined with cognitive fusion based on multiparametric MRI demonstrated good diagnostic performance for the detection of clinically significant prostate cancer. Micro-ultrasound may represent a complementary imaging modality to MRI, particularly in cases of MRI-ultrasound discordance.
MATERIALS AND METHODS: A single-center retrospective study included 185 patients who underwent targeted prostate biopsies between January 2022 and December 2023. Biopsies were all performed with a 29-MHz high-resolution micro-ultrasound system, combined with cognitive fusion based on prior prostate MRI. Primary endpoint was the detection rate of clinically significant prostate cancer defined as ISUP grade ≥ 2. MRI-ultrasound discordances were also analysed, as well as the diagnostic performance of the PRI-MUS score.
RESULTS: The overall prostate cancer detection rate was 68%, with a clinically significant cancer detection rate of 47%. MRI-ultrasound concordance was observed in 152 patients, with a 50% detection rate for ISUP grade ≥ 2 cancers. Among ultrasound targets not identified on MRI, three clinically significant cancers were detected. The PRI-MUS score showed a sensitivity of 75%, a specificity of 36%, and an AUC of 0.66.
CONCLUSION: 29-MHz micro-ultrasound combined with cognitive fusion based on multiparametric MRI demonstrated good diagnostic performance for the detection of clinically significant prostate cancer. Micro-ultrasound may represent a complementary imaging modality to MRI, particularly in cases of MRI-ultrasound discordance.